Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong
1. Teva expects Q2 2025 earnings of 62 cents, $4.29 billion sales. 2. Generics revenue has rebounded with a 5% increase across regions. 3. Analysts cite competition impacting generic Revlimid; growth still anticipated. 4. Teva's management predicts record growth for generics in Q1 2025. 5. Long-term prospects look positive due to planned drug launches and LOE stability.